iCAD seeks US OK for lung cancer detector:
This article was originally published in Clinica
Executive Summary
Computer-aided detection (CAD) provider iCAD is seeking to sell its lung cancer detection product in the US. It has submitted to the FDA a 510(k) application for clearance to market a CAD system for helping to review CT lung scans. The technology identifies roughly-spherical objects in the lung that meet radiologist-specified size, shape and brightness criteria, enabling healthcare professionals to improve workflow by spending more time reviewing potential areas of lung cancer concern, said Nashua, New Hampshire-based iCAD. The company has already formed distribution deals for its lung cancer detection technology with TeraRecon and Viatronix. As for CT-based CAD rivals, R2 Technology last year became the first firm to gain US market clearance to use its ImageChecker system to help identify lung nodules.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.